Sugi Predict

Sugi Predict / Compounds / SCHEMBL19253465

SCHEMBL19253465

SCHEMBL19253465

COC(=O)c1cc(C(=O)OC)n(CC(=O)c2cnn(Cc3ccc(OC)cc3)c2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ KLKB1 P03952 5/20 0.46
▸ CYP1A2 P05177 2/20 0.43
▸ CYP2C19 P33261 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ GRIN1 Q05586 1/20 0.41
▸ GRIN2B Q13224 1/20 0.41
▸ EGLN1 Q9GZT9 1/20 0.40
▸ KDM1A O60341 1/20 0.39
▸ HDAC1 Q13547 1/20 0.39
▸ HDAC2 Q92769 1/20 0.39
▸ HDAC8 Q9BY41 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.39
▸ HDAC5 Q9UQL6 1/20 0.39
▸ MAPT P10636 2/20 0.39
▸ SNCA P37840 1/20 0.39
▸ GRM2 Q14416 1/20 0.39
▸ ALKBH1 Q13686 1/20 0.39
▸ PDE1B Q01064 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28518677 0.94 L3MBTL1 (0.45) L3MBTL1KLKB1CYP1A2CYP2C19SMN1; SMN2
SCHEMBL22449693 0.90 KLKB1 (0.48) L3MBTL1KLKB1CYP1A2CYP2C19SMN1; SMN2
SCHEMBL17801254 0.90 MAPT (0.50) L3MBTL1KLKB1SMN1; SMN2ALDH1A1GRIN1
SCHEMBL19253522 0.87 EGLN1 (0.45) L3MBTL1KLKB1ALDH1A1GRIN1GRIN2B
SCHEMBL19271728 0.84 TUBB4A (0.48) CYP1A2CYP2C19SMN1; SMN2ALDH1A1EGLN1
SCHEMBL1883985 0.81 SMN1; SMN2 (0.55) L3MBTL1CYP1A2CYP2C19SMN1; SMN2ALDH1A1
SCHEMBL17895755 0.79 L3MBTL1 (0.60) L3MBTL1KLKB1SMN1; SMN2ALDH1A1HDAC1
SCHEMBL31131706 0.79 MET (0.36) SMN1; SMN2ALDH1A1MAPT
SCHEMBL29571231 0.78 MAPT (0.43) L3MBTL1KLKB1SMN1; SMN2MAPTGRM2
SCHEMBL2511099 0.76 L3MBTL1 (0.56) L3MBTL1KLKB1GRIN1GRIN2BEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12129256-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives PFIZER INC. (US) 2024-10-29 — — US disclosed
US-20230045252-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2023-02-09 — — US disclosed
US-20230045252-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2023-02-09 — — US disclosed
US-11472809-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives PFIZER INC. (US) 2022-10-18 — — US disclosed
US-11472809-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives PFIZER INC. (US) 2022-10-18 — — US disclosed
EP-3712153-B1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER (US) 2021-12-01 — — EP disclosed
EP-3712153-B1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER (US) 2021-12-01 — — EP disclosed
CN-109071546-B Pyrazolo [1,5-A ] pyrazin-4-yl derivatives as JAK inhibitors 辉瑞大药厂 2021-03-02 — — CN disclosed
US-20200399281-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2020-12-24 — — US disclosed
US-20200399281-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2020-12-24 — — US disclosed
US-10822341-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives PFIZER INC. (US) 2020-11-03 — — US disclosed
EP-3712153-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS Pfizer Inc (US) 2020-09-23 — — EP disclosed
EP-3712153-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS Pfizer Inc (US) 2020-09-23 — — EP disclosed
EP-3419978-B1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER (US) 2020-04-15 — — EP disclosed
EP-3419978-B1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER (US) 2020-04-15 — — EP disclosed
US-20190071448-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2019-03-07 — — US disclosed
US-20190071448-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2019-03-07 — — US disclosed
US-10144738-B2 Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives PFIZER INC. (US) 2018-12-04 — — US disclosed
WO-2017144995-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER INC. (US) 2017-08-31 — — WO disclosed
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2017-08-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12129256-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives CBR3, CNR1, CBR1 L3MBTL1 1343/4885KLKB1 4845/4885CYP1A2 1015/4885
US-20230045252-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES CBR3, CNR1, CCR6 L3MBTL1 1530/4885KLKB1 4840/4885CYP1A2 1267/4885
US-10822341-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives CBR3, CNR1, CCR6 L3MBTL1 1530/4885KLKB1 4840/4885CYP1A2 1267/4885
US-10144738-B2 Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives JAK1, JAK2, JAK3 L3MBTL1 2410/4885KLKB1 3421/4885CYP1A2 1324/4885
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES CBR3, CNR1, CCR6 L3MBTL1 1530/4885KLKB1 4840/4885CYP1A2 1267/4885
US-20200399281-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES CBR3, CNR1, CBR1 L3MBTL1 1343/4885KLKB1 4845/4885CYP1A2 1015/4885
US-20190071448-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES CBR3, CNR1, CCR6 L3MBTL1 1530/4885KLKB1 4840/4885CYP1A2 1267/4885
US-11472809-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives SYMPK, IL15, STAT6 L3MBTL1 2811/4885KLKB1 468/4885CYP1A2 830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.